Stem cell transplant for nerve damage from homocysteine remethylation disorders
Part of Blood & lymphatic, Brain & nervous system, Genetic & congenital clinical trials.
This trial tests whether a stem cell transplant using your own cells can help treat nerve damage caused by a rare genetic condition that affects homocysteine levels. It may be an option if standard treatments have not worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You have been diagnosed with a hereditary homocysteine remethylation disorder, confirmed by clinical, biochemical, and genetic tests.
- You have nerve-related symptoms such as trouble walking, balance problems, memory issues, or brain changes seen on scans.
- You have tried standard treatments like folic acid, vitamin B12, or betaine, but they have not worked well enough.
- Your homocysteine levels remain high (over 50 umol/L) despite treatment.
- You have not had a stem cell transplant before, and you do not have severe organ problems, active infections, or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a transplant of special cells from donated umbilical cord blood can help slow or improve symptoms of ALS (amyotrophic lateral sclerosis, also called Lou Gehrig's disease). The cells may help repair nerve damage and reduce disease progression.
This study tests whether bone-marrow stem cells can improve nerve function in people with nerve damage that usually doesn’t recover with current care. It also checks whether the treatment is safe and whether people can be followed over time with repeated nerve exams.
This trial uses your own blood stem cells to reboot your immune system, which may help stop multiple sclerosis attacks and slow disability. It is for people with active MS that has not responded well to other treatments.
This trial tests a gene-correction treatment that changes sickle hemoglobin (HbS) into normal hemoglobin (HbA) using your own stem cells. It may help reduce severe sickle cell complications for people with severe disease who meet specific safety and medical criteria.
This Phase 1 study tests whether adding a patient’s own nerve support cells to a severely injured nerve is safe and helpful. It’s for people with recent major nerve damage in an arm or leg, with strict safety checks.
This trial tests whether a stem cell transplant from a partially gene-matched family member can cure severe sickle cell disease in children and young adults. The transplant uses a new approach that may work even when a perfectly matched sibling isn't available, and it might help patients whose sickle cell is causing serious complications like strokes, organ damage, or frequent pain crises.
Hear when a new Hereditary Homocysteine Remethylation Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.